PPARA and inflammatory bowel disease: Furthermore, it was demonstrated that treating mitochondrial dysfunction in the colon using the PPAR agonist 5-ASA [79], consistent with the dysfunctional PPAR signaling associated with S89A mutation, ameliorated signs of disease in mice with pre-IBD and normalized the microbiota composition by restoring epithelial hypoxia [77].